Royalty Report: Drugs, Cancer, Vaccine – Collection: 306612

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Vaccine
  • Immune
  • Drug Discovery
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Biotechnology
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 306612

License Grant
Licensor, a nonprofit organization providing investigators and clinicians scientific, granted exclusive worldwide rights to several U.S. and foreign patents and patent applications.
License Property
The patents and patent applications covering methods of using GP2 as an immunotherapy that elicits a targeted immune response against HER2/neu-expressing cancers.

GP2 is an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The patents are titled Vaccine for the Prevention of Breast Cancer Recurrence, and, Targeted Identification of Immunogenic Peptides.

GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a Phase IIb clinical trial completed in 2018, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months.

Following breast cancer surgery, a HER2/neu 3+ patient receives Herceptin in the first year, with the hope that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting while Kadcyla has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting.

Patent 1 –
Title Vaccine for the Prevention of Breast Cancer Recurrence
Provisional Patent Application No. 61/121,220

Patent 2 –
Title Targeted Identification of Immunogenic Peptides
as described in U.S. Patent Application No. 12/045,402 filed on 3/10/2008 and Australian Application No. 2008201427 filed on 3/28/2008, both claiming priority to U.S. Provisional Application No. 60/714,865 filed on 09/08/2005 and International Application No. PCT/US2006/035171 filed on 09/08/2006; and
as described in International Application No. PCT/US2006/035171 filed on 09/08/2006 and all corresponding National Stage Applications including but not limited to Japanese Patent Application No. 2008-530244, European Patent Application No. 06824918.4 filed on 3/31/2008, and Canadian Patent Application No. 2,622,036 filed on 3/10/2008; and
as described in International Application No. PCT/GB2008/050227 filed 03/28/2008 and all its corresponding National Stage Applications

Field of Use
The field of use is to develop and advance GP2 immunotherapy towards commercialization.

The Field means (a) all fields of use with respect to Patent titled Vaccine for the Prevention of Breast Cancer Recurrence; and (b) use of the HER family peptide GP2 in combination with Herceptin® and only in the field of human therapeutics with respect to Patent titled Targeted Identification of Immunogenic Peptides.

This agreement is in support of the GP2 breast cancer vaccine Phase II clinical trial.

Licensee believes that GP2 may be used to address the 50% of recurring cancer patients who do not respond to either Herceptin or Kadcyla in the treatment of breast cancer.

IPSCIO Record ID: 310513

License Grant
The Foundation conducted a clinical study for the Company for two phase II clinical trials to determine if a vaccine containing AE37 plus GM-CSF or another peptide vaccine compound (GP2) plus GM-CSF improved patient outcomes. Pursuant to the Forbearance Agreement, the Company and the Foundation in exchange for the Foundations deferring the Company’s overdue payments, future payments and interest, the Company agreed, among other things to pay the Foundation certain royalties and accelerated payments.
License Property
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.

In 2006 Phase I clinical trial was completed of AE37 in breast cancer, including a phase Ib safety and immunology study of AE37 in combination with GM-CSF in 16 breast cancer patients who had completed all first-line therapies and who were disease-free at the time of enrollment to the study (Holmes et al. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;263426-33).

The Foundation conducted the study, under the sponsorship of an institute affiliated with the United States Military until the IND #12229 was transferred to the Company, after which Foundation continued trial management on behalf of the Company.

The Foundation is a nonprofit organization dedicated to advancing medicine by administering, managing and supporting preeminent scientific programs.

Field of Use
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is for the treatment of breast cancer.

Licensee is an oncology company focused on the modulation of the immune system to treat cancer and is developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key.

IPSCIO Record ID: 322039

License Grant
The parties collaborated to globally develop and commercialize Licensor’s ladiratuzumab vedotin (MK-6440). The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.

Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.

License Property
Ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors.

Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.

HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.

Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.

Field of Use
The field of use is for the treatment of cancer such as breast cancer.

HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).

Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.

IPSCIO Record ID: 344536

License Grant
Licensor grants the Licensee of Korea, an exclusive, non-transferable license, limited to the Licensed Territory and Field of Use, to the Licensed Intellectual Property to use, sell, offer for sale, or otherwise commercially exploit the Licensed Products supplied by Licensee within the Licensed Territory and Field of Use for the Term of this Agreement.
License Property
Licensor shall supply Licensee with Licensed product known as the commercial product NeuVax (E75 peptide in combination with GM-CSF) as a packaged finished product.  NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab.  

The licensed intellectual property includes the following patents
— Methods And Compositions For Stimulating T-Lymphocytes
— Compositions Containing Immunogenic Molecules and Granulocyte-Macrophage Colony Stimulating Factor, as an Adjuvant
— Controlled modulation of amino acid side chain length of peptide antigens
— Vaccine for the Prevention of Breast Cancer Relapse

Field of Use
The Field of Use shall mean for the treatment of breast cancer.

IPSCIO Record ID: 369313

License Grant
Licensor, a non-profit cancer treatment and research institution, grants the exclusive right and license, with the right to sublicense, to make, have made, use, lease and sell the Licensed Products in the Territory for the Field of Use.
License Property
The Invention shall mean the inventions claimed or described in Patent Rights titled Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma associated antigen.
Field of Use
Licensee is developing the MUC-1 peptide-based vaccine BLP-25 for the potential treatment of cancer. It is in phase II trials for non-small cell lung cancer (NSCLC). The MUC-1 mucin secreted by cancer cells has been shown to decrease the activity of certain immune response cells, including killer T-cells, and can inhibit the immune T-cell response by > 70%. BLP-25 is designed to target an immune response to the MUC-1 mucin that is shown by > 90% of common solid tumors.

The Field of Use shall mean in vivo, ex vivo, or in vitro prophylactic or therapeutic uses of Licensed Product in the treatment or prevention of cancer in humans.

IPSCIO Record ID: 369382

License Grant
For the Exclusive Licenses, Licensor grants
–  an exclusive license, including the right to sublicense, under the Licensor Patent Rights, to research, develop, make, have made, use, sell, offer for sale, supply, cause to be supplied and import Compounds and Licensed Products in the Territory;
–  an exclusive license, including the right to sublicense, to use Licensor Technology and Confidential information in connection with the research. development, making, having made, use, sale, oiler for sale, supply, causing to be supplied and importation of Compounds and Licensed Products in the Territory;
–  an exclusive license, including the right to sublicense, under the Licensor Patent Rights to research, develop, make, have made, use, sell, offer for sale, supply, cause to be supplied and import Diagnostic Assays in the Territory; and
–  an exclusive license, including the right to sublicense, to use Licensor Technology and Confidential information in connection with the research, development, making, having made, use, sale, offer for sale, supply, causing to be supplied and importation of Diagnostic Assays in the Territory.

For the Non-Exclusive Research License, Licensor grants a non-exclusive, irrevocable, perpetual license in the Territory, with the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology and Confidential Information disclosed to Licensee during the Term, excluding any Patent Rights relating thereto.

License Property
Licensor owns or otherwise controls certain patents, patent applications, technology, know-how and scientific and technical information relating to an EGFRvIII mutant peptide comprising the amino acid sequence LYS-LYS-GLY-ASN-TYR.

CDX-110 means the EGFRvlll mutant peptide consisting of the amino acid sequence LEU-GLU-GLU-LYS-LYS-GLY-ASN-TYR-V AL-V AL-THR-ASP-HIS covalently linked to a Cysteine and conjugated to keyhole limpet hemocyanin (KLH).  CDX-110 is a therapeutic cancer vaccine candidate.

Compound means a peptide that comprises at least a portion of an EGFRvIII comprising the amino acid sequence LYS-LYS-GLY-ASN-TYR. as an antigen. alone or as a component of a larger peptide. protein or molecule.

EGFRvIII means EGFR variant III peptide, a variant of EGFR. previously referred to as a type II variation of EGFR, consisting of the amino acid sequence of EGFR as set forth in GenBank Accession No, CAA2524Q. except amino acids number 1 through 24 have been deleted and where amino acids number 30 through 297 have been replaced by a Glycine. and naturally occurring variants thereof.

Additional Component means a therapeutically active (alone or in combination) adjuvant. immunomodulator. immunoregulator or hapten.

APC Product means an antibody or fragment thereof. that is targeted to an antigen-presenting cell (APC) and that comprises or is connected to a Compound or Licensed Product.

Patents are for the EGFRvlll Patent Family 1, 2, and 3.

Field of Use
The field of use for CDX-110 includes the treatment of glioblastoma multiforme or GBM.

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain.

Rindopepimut is an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII) in patients with Glioblastoma Multiforme (GBM)

IPSCIO Record ID: 189409

License Grant
Licensor hereby grants to the Licensee, a subsidiary, an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.
License Property
The license is for Patent Application Serial No. 62/478532, titled as Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization and commercially named StemVacs.

The patent describes methods of cancer treatment through the administration of proteins or specific peptides found on tumor stem cells in vivo, in a manner eliciting monocyte or dendritic cell migration in order to allow uptake of proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor initiating stem cells.

Field of Use
This agreement is for the vaccine industry.

IPSCIO Record ID: 30031

License Grant
The company granted an exclusive development and commercialization license to use maytansinoid ADC (antibody-drug conjugates) technology with antibodies, such as trastuzumab, or other proteins that target HER2.
License Property
Kadcyla is a HER2-targeting ADC that consists of trastuzumab antibody with our DM1 cell-killing agent attached using one of our engineered linkers.
Field of Use
In February 2013, the U.S. FDA granted marketing approval to the HER2-targeting ADC compound, Kadcyla.

KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery.

IPSCIO Record ID: 6674

License Grant
The Canadian Licensor hereby grants to the Canadian Company for the Licensed Field and in the Licensed Territory, a worldwide exclusive license to exploit the Assets, particularly including but not limited to the Patents, to develop and have developed, to make and have made (including contract production by a toll manufacturer), to use and have used, and to sell or have sold, and otherwise dispose of, Licensed Product.
License Property
The license is non-exclusive with respect to diagnostic  applications for P. haemolytica antibodies and excludes applications related to infectious diseases.

Norelintm is a therapeutic vaccine designed to stimulate in patients production of antibodies against GnRH, resulting in reduced production of hormones that may cause or contribute to the growth of certain sex-hormone dependent cancers.  It has completed a Phase I/II safety and immunogenicity trial in hormone-sensitive prostate cancer suggesting that the approach may be better tolerated than currently available therapies.

Compositions and Treatments for Pneumonia in Animals

Issued U.S. Patent No. 5,849,531 a

Leukotoxin Vaccine Compositions and Uses Thereof

Issued U.S. Patent No. 5,871,750 a

Pasteurella haemolytica Leukotoxin Compositions and Uses Thereof

Issued U.S. Patent No. 5,476,657 a

B.       Robins and Associates Patent Series 9001-0016

Enhanced Immunogenicity Using Leukotoxin Chimeras

         U.S. Application 08/976,566 a

         U.S. Patent 5,708,155 a

         U.S. Patent 5,422,110 a

GnRH Leukotoxin Chimeras

         U.S. Application 09/383,912 a

         U.S. Patent 5,969,126 a

         U.S. Patent 5,723,129 a

         U.S. Patent 5,837,268 a

         U.S. Patent 6,022,960 a

Field of Use
Licensed Field means, and is limited to, the exploitation of the Assets in respect of Licensed Products for use in humans, comprising Gonadotrophin Hormone Releasing Hormone (GnRH), Pasteurella haemolytica proteins or peptides combined with GnRH or Epidermal Growth Factor Receptors or Epidermal Growth Factor Receptor Ligands as defined in Exhibit B hereto, and for clarity excludes all products comprising GDF-8 or Myostatin, and further excludes applications of the Assets and the Patents relating to the diagnosis, treatment, or prevention of infectious diseases.  Assets and know-how in the field of GnRH vaccines and immunological carriers based on Pasteurella haemolytica for humans by, amongst other activities, performing preclinical investigations and a clinical investigation of a certain product, Norelin.

IPSCIO Record ID: 217567

License Grant
Licensor granted Chinese Licensee an exclusive license to use Licensor’s patents, know-how, data and other intellectual property relating to Licensor’s AE37 peptide to develop and sell products for the prevention and treatment of prostate cancer in China (including Taiwan, Hong Kong and Macau).
License Property
Peptide name AE37 (li-Key/HER2/neu776-790)

AE37 is an immunotherapeutic vaccine for prostate cancer.  AE37, an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Trade name AE37

Field of Use
AE37 peptide is to develop and sell products for the prevention and treatment of prostate cancer.

IPSCIO Record ID: 256328

License Grant
This amendment revises the listed patents.  Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.

IPSCIO Record ID: 369311

License Grant
Licensor of the Netherlands grants to Licensee of Germany a license under the Licensor Technology  to use, import, develop, market and sell and have used, imported, developed, marketed and sold product in the Field in the NA Territory and the ROW Territory.

This agreement includes a non-exclusive grant back to Licensor by Licensee.

License Property
Licensor has technology related to, inter alia, the development of BLP25.

The Product means BLP25.

BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.

MUC1 means cancer associated mucin-1.

L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.

Field of Use
BLP25 Liposome Vaccine (L-BLP25) is currently in development for the treatment of non-small cell lung cancer (NSCLC).  Licensee will take over administrative and financial responsibility for the development and commercialization of L-BLP25, including the planned phase 3 trial in NSCLC

The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.

IPSCIO Record ID: 364016

License Grant
Licensor hereby grants to Licensee an exclusive license, subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.

Licensor also hereby grants to Licensee an exclusive license to make, use, and/or sell the Licensed Materials in the Territory for the Field of Use. At Licensees request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

License Property
Protein GP96 Vaccination (UMD-107) technology is a platform designed to activate immune responses against cancer or infectious diseases.

U.S. patent application serial number US 61/033,425 entitled 'Heat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 20 March 2008;
PCT patent application number PCT/US2009/001727 entitled 'bleat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 19 March 2009;
all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT patent application number PCT/US2009/001727 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.

“Patent Rights” shall mean the following United States Patent applications  U.S. patent application serial number US 61/033,425 entitled “ Allogeneic Cancer Cell-Based Immunotherapy” and files on 3 March 2008; PCT patent application number PCT/US2009/001330 entitled “Allogeneic Cancer Cell-based Immunotherapy” and filed on 3 March 2009; all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT application number PCT/US2009/001330 to meet the requirements of 35 U.S.C. 112¶1; and any re-examination or reissues of the foregoing.

Field of Use
Field of Use is for the treatment of cancer relating to all human healthcare and research applications.

IPSCIO Record ID: 263928

License Grant
With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.
License Property
GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.
Field of Use
The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 364010

License Grant
Licensor hereby grants to Licensee and exclusive license. Subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.  

Licensor also hereby grants to Licensee an exclusive license to make. use. and/or sell the Licensed Materials in the Territory for Field of Use.  At Licensee’s request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

Licensor grants to Licensee a six (6) month exclusive option to negotiate a worldwide royalty-bearing, exclusive license with right to sublicense for any Improvement.

License Property
The Podack Cancer Vaccine (UM97-14) technology shall mean the technology relating to a cell-based vaccine for treating cancer patients utilizes human cancer cells that have been engineered to secrete gp96.  The presently preferred version of the vaccine uses the AD100 human lung adrenocarcinoma cell line transfected with constructs that encode III.A-AI and gp96-Ig (heat shock protein gp96 fused to Fe region of IgGI).  In a presently preferred protocol, NSCLC patients are intradermermally administered several injections of 5×107 vaccine cells each at two week intervals.

Licensed Product shall mean any product or part thereof which
(a) is covered in whole or in part by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights
(b) is manufactured by using a process which is covered in whole or in party by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights or
(c) incorporated or comprises the Podack Cancer Vaccine (UM97-14) or the cell line “AD100-gp96/III.A”.

Patent Rights shall mean the following United States Patent applications  U.S. provisional patent application serial number 60/075.358 entitled “Modified Heat Shock Protein-antigenic Peptide Complex” and filed on February 20, 1998  U.S. patent application serial number 09 253.439 entitled “Modified Heat Shock Protein-Antigenic Peptide Complex” and filed on February 19, 1999  U.S. patent  application serial number 11/878.460 entitled “Recombinant Cancer Cell Secreting Modified Heat Shock Protein-antigenic Peptide Complex” and filed on July 24, 2008  all United States patents and foreign patents and patent applications based on these U.S. applications  all divisionals, continuations of the foregoing  and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. provisional patent applications serial number 60/075.358.  U.S. Patent application serial number 09 253.439, or U.S. patent application serial number 11/878.460 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.  â€œPatent Rights” shall not include Excluded Patent Rights.

Licensed Materials shall mean any modified AD100 cell lines that have been engineered to secrete gp96.

Field of Use
Field of Use is for treating cancer patients and shall mean all human healthcare and research applications.

IPSCIO Record ID: 345562

License Grant
English Licensor granted a nonexclusive license to Licensee to produce and characterize potential product candidates using the Company’s viral vector technology and to provide research services to Licensee during the research term which commenced on June 2019 through the end of 66 months and for up to six vaccine products based on antigens discovered via Licensee’s proprietary platform.
License Property
Viral vector technology is known as ChAdOx1 and ChAdOx2.  This platform comprises several components that, when combined, allow the developed product candidates designed to induce high and durable levels of antigen-specific T cells and B cells, to prevent and treat infectious diseases and cancer.

ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.

Field of Use
Field of use is for the immunotherapy and vaccine fields.

IPSCIO Record ID: 324645

License Grant
University hereby grants to Licensee the worldwide non-exclusive right and license in the Field, with the right to sublicense subject to this agreement, to make, have made, use, sell, offer for sale and import Licensed Products and to practice under the Patent Rights until the expiration of the last to expire claim of the Patent Rights, unless this Agreement is terminated sooner as provided herein.
License Property
7,297,337 – EphA2 T-cell epitopes and uses therefor
8,114,407 – EphA2 T-cell epitopes and uses therefor
Field of Use
Field shall mean use of Licensed Product or Patent Rights in or packaged with Licensee’s Proprietary Vaccine for administration to humans for the diagnosis, prevention and treatment of diseases and tumors of the brain. For the avoidance of doubt the Field specifically excludes use of Licensed Products and/or Patent Rights in the development of therapeutic vaccines or diagnostic tests for breast, ovarian, liver, pancreatic, colon and lung cancers.

Proprietary Vaccine shall mean a vaccine which is developed or being developed for a therapeutic indication based on biological activity that is solely-owned or in-licensed by Licensee from third parties and which is not covered by the Patent Rights and which is not Licensed Product hereunder. For the avoidance of doubt, the Il-13 Alpha2 Peptide Analogues licensed under the Exclusive Patent License Agreement shall constitute a Proprietary Vaccine.

IPSCIO Record ID: 279358

License Grant
Licensor, a non-profit cancer treatment and research institution,  grants an exclusive worldwide right and license under the Patent Rights in the Field of Use, including the right to sub license, to make, have made, use, have used, lease, sell, have sold, offer to sell, import, and have imported Licensed Products and to use, practice or have practiced Licensed Processes.
License Property
The patents include Synthetic HLA binding peptide Analogues and Uses Thereof, and,  WT-1 HLA Class II binding peptides and Compositions and Methods Comprising Same.

INNO-305 (WT1) Immunotherapy
Wilms tumor protein, or WT1, is a well known and well characterized protein found in the human body. WT1 is normally produced at the embryonic stage of human development and, as people age, expression of the protein is reduced and nearly eliminated. In normal adults, WT1 is present but at very low levels. However, in the case of certain cancers including, acute myelogenous leukemia, or AML, chronic myelogenous leukemia, non-small cell lung cancer and mesothelioma, the protein is found in very high levels. Because normal levels of WT1 are low and cancer levels of WT1 are high, we believe WT1 is an attractive target for cancer immunotherapy.

Field of Use
The Field of Use shall mean the use of WT-1 polynucleotides and peptides, and mutants and derivatives thereof, and peptides, antibodies/tetramers and vaccines developed therefrom, for research and development and to treat, diagnose and prevent cancers and other diseases, disorders or conditions.

IPSCIO Record ID: 256326

License Grant
This amendment is to revise and amend the Agreement to add the Collaboration Compound known as GI-6100 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-3000 as a Drug Candidate under the Agreement.  The patents are also updated.

This amendment adds for the CRADA Research License,  Licensor grants the non-exclusive, worldwide, nontransferable and non-sublicensable license, under the Licensed Intellectual Property, solely as necessary to support research and development activities conducted by the NIH under the CRADA or Cooperative Research and Development Agreement for lntramural-PHS Clinical Research that pertain to certain Collaboration Compounds.

License Property
The candidate compounds
GI-4000 means the series of Tarmogen products that express mutated Ras and/or one or more peptides thereof. GI4014, GI-4015, GI-4016 and GI-4020 arc part of the GI-4000 series and are the subject of [IND No. BB-IND 11653].

GI-6200 means the series of Tarmogen products that solely express human carcinocmbryonic antigen (CEA). GI6207 is part of the GI-6200 series and means the single Tarmogen product that is the subject of [IND No. BB-IND 13934 (drug master file BB-MF 13884)], and that solely expresses human CEA having a N6lOD mutation.

GI-6l00 means the series of Tarmogen products that express human MUC- I antigen(s). GI-6108 is part of the GI-6l00 series and is the single Tarmogen product that is the current lead product for the GI-6100 program. GI-6108 is currently undergoing preclinical development at the National Institutes of Health under the terms of the CRADA.  As of the Amendment #5 Effective Date, GI-6l08 is believed to be the specific product intended to be subject of [an IND to be filed by the NIH under the CRADA. Should a different Tarmogen product expressing MUC-1 antigen(s), other than GI-6108, be selected for said IND], then it is understood such product shall become the Drug Candidate associated with the GI-6100 designation.

Gl-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that is the subject of [BB-IND 14895].

Field of Use
The focus of the compound in this agreement is for the treatment of cancer.
GI-4000 series target tumors with mutations in a protein called Ras.

IPSCIO Record ID: 280840

License Grant
Licensor hereby grants to Licensee an exclusive license under the Licensed Patents in the Territory to make, have made, develop, use, practice, import, export, distribute, market, promote, offer for sale, and sell Licensed Products in the Licensed Field.

Licensor hereby grants to Licensee a non-exclusive license in the Territory under Licensor’s rights in the Know-How to use and practice any method, process, or procedure within the Know-How and otherwise use and exploit the Know-How; all in the Licensed Field; provided however, that with respect to Project Information, such non-exclusive license shall be limited to the Project Information Licensed Field.

License Property
The technology relates to drugs used in the treatment of various cancers.

Licensed Patents means
Patent Applications 61/249,596; 61/423,842; 61/423,825; 61/392,296; 61/423,832; 61/254,395; 61/423,838

1.
REVERCOM

·
Drug summary Liposome-packaged combination of proprietary molecule, inhibitor of multidrug resistance transporter, and conventional chemotherapeutic agent.

·
Potential use adjuvant applied as part of chemotherapy of cancer patients.

2.
MOBILAN

·
Drug summary Adenovirus-based treatment inducing immune response. Ready for final stage of preclinical development.

·
Potential use Universal anti-cancer vaccine.

3.
ARKIL

·
Drug summary Androgen receptor inhibitor, prepared for Hit-2-Lead optimization studies.

·
Potential use Nanodrugs for treatment of prostate cancer (both hormone (androgen)-dependent and –independent/refractory forms).

4.
ANTIMYCON

·
Drug summary MYC inhibitor.

·
Potential use Drugs for treatment of a broad range of solid tumors (breast, prostate, colon, non-small cell lung carcinoma, etc.) and hematological malignancies.

Projects and Licensed Patents
1. Projects

Drug
Definition

Mobilan = Research, development and support of an immunotherapeutic drug candidate based on recombinant adenovirus vector, stimulating immune response in humans as a vaccine-like treatment for cancer or other indications.

Revercom = Research, development, formulation and support of a drug candidate based on proprietary Reversan compound as an adjuvant for chemotherapy.

Antimycon = Research, development, lead optimization, formulation and support of a drug candidate regulating cMyc transcription factor for cancer indications.

Arkil = Research, development, lead optimization, formulation and support of a drug candidate regulating androgen receptor for prostate cancer.

Xenomycin = Research, development, lead optimization, formulation and support of a drug candidates based on proprietary Curaxin family of compounds for anti-infective/anti-biotic/anti-fungal applications.

2. Licensed Patents

Product
Title
Inventors
Country
Application No.
Patent No.

MOBILAN = Use of Toll-Like Receptor and Agonist for Treating Cancer
Andrei Gudkov (RPCI, CBLI)
U.S.
61/249,596
n/a

MOBILAN = Toll-like receptor 5 agonist produced and secreted by mammalian cells
Andrei Gudkov (RPCI), Venkatesh Natarajan (RPCI)
U.S.
61/423,842
n/a

MOBILAN = Functional bacreriophage-based nanoparticles coated by Toll-like receptor 5 agonist
Andrei Gudkov (RPCI, CBLI), Venkatesh Natarajan (RPCI)
U.S.
61/423,825
n/a

ANTIMYCON = Small molecules inhibiting oncoprotein MYC
Andrei Gudkov (RPCI), Catherine Burkhart (CBLI), Mikhail Nikiforov (RPCI), Michelle Haber (CCIA), Murray Norris (CCIA)
U.S.
61/392,296
n/a

ANTIMYCON = Small Molecules Inhibiting Oncoprotein MYC
Andrei Gudkov (RPCI), Catherine Burkhart (CBLI), Mikhail Nikiforov (RPCI), Michelle Haber (CCIA), Murray Norris (CCIA)
U.S.
61/423,832
n/a

ARKIL = Method for treating androgen receptor positive cancers
Katerina Gurova (RPCI), Natalia Narizhneva (CBL)
U.S.
61/254,395
n/a

REVERCOM = Dual cargo nanoparticles combining MRP1 inhibitors with chemotherapeutic drugs
Andrei Gudkov (RPCI, CBLI), Aridam Sen (RPCI), Catherine Burkhart (CBLI), Padmaja Kunapuli (RPCI)
U.S.
61/423,838
n/a

Field of Use
“Application” means the intended use for a Licensed Product, including the diagnosing, treating, curing, mitigating, and/or preventing a disease or other condition in a human or other animal, such as small cell lung cancer, large cell lung cancer, or other specific disease state.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.